Exclusive: Nornickel in talks with China Copper to move smelting plant to China, sources say
HONG KONG, July 9 (Reuters) - Nornickel (GMKN.MM), opens new tab is in talks with China Copper to form a joint venture that would allow the Russian mining giant to move its entire copper smelting base to China, four sources with knowledge of the matter told Reuters.
If the move goes ahead, it would mark Russia's first uprooting of a domestic plant since the U.S. and Britain banned metal exchanges from accepting new aluminium, copper and nickel produced by Russia.
It also means Nornickel's copper will be produced within the country where it is most consumed.
Nornickel said in April it planned to close its Arctic facility and build a new plant in China with an unnamed partner.
Executives at China Copper, owned by the world's largest aluminium producer Chinalco (601600.SS), opens new tab, flew to Moscow in June to discuss a possible joint venture, one of the sources said, adding that details of the structure and investment are still under discussion.
Nornickel declined to comment. Chinalco and China Copper did not respond to requests for comment via email and phone.
Sites being considered in China include Fangchenggang and Qinzhou in the Guangxi region, the two sources said, with another source saying Qingdao in Shandong province was also possible.
A decision on a joint venture will be made over the next few months, a fifth source said, adding that Nornickel's Chinese output is likely to be consumed domestically.
The new facility will have capacity to produce 450,000 tonnes of copper annually, two of the sources said, amounting to around 2% of global mined supplies estimated at around 22 million metric tons this year.
Nornickel, which according to its annual report produced 425,400 tonnes of refined copper last year, processed all of its concentrates in 2023 at the Arctic plant, its only operation producing finished copper suitable for delivery to exchanges.
Google Pixel 9 series phones will use Qualcomm ultrasonic fingerprint recognition technology
Google's new generation of flagship smartphone Pixel 9 series is expected to be officially released in mid-August, and the new machine is likely to be equipped with ultrasonic fingerprint recognition technology for the first time to replace the original optical fingerprint recognition. According to core intelligence, Google Pixel 9 series will use the same Qualcomm 3D Sonic Gen 2 ultrasonic fingerprint recognition sensor as the Samsung Galaxy S24 Ultra. This ultrasonic technology under the screen fingerprint sensor is Qualcomm released at the CES2021 conference, compared with the previous generation of solutions, the module thickness is further reduced to 0.2mm, while the scanning area is expanded to 8mm×8mm, that is, the recognition area is increased by 77%. This will also allow users to realize fingerprint recognition without having to point their fingertips 100% accurately at the identification area indicated on the screen.
It may be getting harder to leave your smart wearable for the sake of your health
The world's first portable electrocardiograph was an 85-pound backpack, and now a 10-gram patch attached to your chest can transmit electrocardiograms uninterrupted for two weeks. The Apple Watch, which is worn by an estimated 100 million people, can send a text message to alert people when their heartbeat is irregular. Wearable sensors on the arms, wrists and fingers can now report arrhythmias, blood sugar levels, blood oxygen and other health indicators. Medical journals have also proposed a more ambitious vision - wearable devices can monitor patients with chronic diseases, eliminating the need for frequent hospital visits. They can spot potential health problems before a stroke or diabetes develops. The forces of health technology and wearables are converging. Tech giants like Apple (AAPL) and Alphabet's (GOOGL) Google are adding health features to their products. Medical technologists like electrocardiogram patch maker iRhythm Technologies or blood sugar monitor makers DexCom (DXCM) and Abbott Laboratories (ABT) are taking their devices beyond the clinic. "In the sensor world, people started on the consumer side and wanted to get into health care," said Kevin Sayer, chief executive of Decon Medical. "In health care, we're trying to be more consumer oriented, and I think all of those things are sort of colliding." Early bets favored the tech giants, with every health-related announcement from Apple, Google or Samsung Electronics hitting medical tech stocks. But changing doctors' practices will also require sustained investment in clinical trials. Big tech companies have cut back on investments in health care. Now it seems that medical technologists will be at the vanguard of the digital health revolution - with smartwatches and smart rings bringing them more customers who need to be diagnosed. Blake Goodner, co-founder of Bridger Management, a hedge fund focused on health care, said: "A group of medtech companies focused on digital health are maturing and reaching a scale where they can not only be profitable but also make investments to compete with larger tech companies." Tech giants aren't getting out of the health business. Apple's smartwatch has an electronic heart rate sensor that generates a single-point electrocardiogram, a wrist temperature sensor, and an accelerometer that can detect violent falls. Hundreds of millions of people are wearing smartwatches with health features from Apple or its rivals Samsung and Garmin.
Iran's president-elect reaffirms policy toward Israel
Iran's President-elect Masoud Pezeshkian reiterated Iran's anti-Israel stance on Monday, saying resistance movements across the region will not allow Israel's "criminal policies" against Palestinians to continue. Pezeshkian told Hassan Nasrallah, the leader of Iran-backed Lebanese Hezbollah, that "the Islamic Republic will always support the people of the region in their resistance against the illegal Zionist regime." This suggests that the incoming government will not change its regional policy under the relatively moderate Pezeshkian, who defeated his hard-line opponent in a runoff election last week. Pezeshkian was quoted as saying by Iranian media, "I am sure that the regional resistance movement will not allow this regime to continue its militant and criminal policies against the oppressed people of Palestine and other countries in the region." The Shiite Muslim Hezbollah and the Palestinian Sunni Muslim Hamas are both part of the local "resistance axis" faction organization supported by Iran. Israel did not immediately comment on Pezeshkian's speech. Hamas led an attack on southern Israel on October 7. According to Israeli statistics, Hamas killed 1,200 people and kidnapped about 250 hostages, triggering the Israeli-Palestinian war. The Gaza Health Ministry said that the Israeli military attack killed more than 38,000 Palestinians and injured nearly 88,000 people.
South African rand stable as markets await US interest rate hints
JOHANNESBURG, July 9 (Reuters) - The South African rand was little changed in early trade on Tuesday, as markets awaited the Federal Reserve chair's testimony in Washington and U.S. June inflation data for clues on the country's future interest rate path. At 0644 GMT, the rand traded at 18.1300 against the dollar , near its previous close of 18.1175. "The rand has opened marginally softer at 18.13 this morning, and we expect trading to remain range-bound in the short term," said Andre Cilliers, currency strategist at TreasuryONE. Markets will listen to the tone of Fed Chair Jerome Powell's testimony in Washington on Tuesday and Wednesday and look to June inflation data out of the U.S. later this week for hints on the future interest rate path in the world's biggest economy. "Analysts will be gauging the Fed's response to the recent softer U.S. economic and labour data, with markets already starting to price in two rate cuts this year," Cilliers added. The risk-sensitive rand often takes cues from global drivers like U.S. economic policy in the absence of major local factors. South Africa's benchmark 2030 government bond was slightly stronger in early deals, with the yield down 1 basis point at 9.74%.
Doctors visited the White House 8 times? White House: Biden did not receive treatment for Parkinson's disease
White House spokeswoman Karina Jean-Pierre denied a report in the U.S. media on the 8th that President Joseph Biden did not receive treatment for Parkinson's disease. Biden had the first televised debate of the 2024 presidential election with Republican opponent Donald Trump on June 27, and his poor performance on the spot triggered discussions about his physical condition. The New York Times reported that a doctor specializing in the treatment of Parkinson's disease had "visited" the White House eight times from August last year to March this year. Facing the media's questions about Biden's health, Jean-Pierre asked and answered himself at a regular White House press conference on the 8th: "Has the president received treatment for Parkinson's disease? No. Is he currently receiving treatment for Parkinson's disease? No, he is not. Is he taking medication for Parkinson's disease? No." Jean-Pierre said Biden had seen a neurologist three times, all related to his annual physical examination. She also took out the report issued by the doctor after Biden's most recent physical examination in February this year. The report said, "An extremely detailed neurological examination was once again reassuring" because no symptoms consistent with stroke, multiple sclerosis or Parkinson's disease were found. The doctor who went to the White House mentioned by the New York Times is Kevin Kanal, a neurology and movement disorder expert at the Walter Reed National Military Medical Center in Maryland and an authority on Parkinson's disease. Jean-Pierre suggested that the doctor might have come to treat military personnel on duty at the White House.